Slow Down The Adaptive Trials Train, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
More definitions are needed to ensure that adaptive clinical trials are "not a fad but an innovation," agency tells PhRMA-sponsored workshop.
You may also be interested in...
FDA To Issue Five Guidances On Adaptive Clinical Trial Design
The agency will issue a total of five guidance documents regarding adaptive clinical trials, the first of which will examine using multiple endpoints in the same trial.
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.